General Information of the Compound
| Compound ID |
CP0017474
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Compound Name |
DECERNOTINIB
Show/Hide
|
||||||||||||||||||
| Synonyms |
(2r)-2-Methyl-2-[[2-(1h-Pyrrolo[2,3-B]pyridin-3-Yl)pyrimidin-4-Yl]amino]-N-[2,2,2-Tris(Fluoranyl)ethyl]butanamide
(R)-2-((2-(1H-Pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)amino)-2-methyl-N-(2,2,2-trifluoroethyl)butanamide
944842-54-0
Adelatinib
CHEMBL3039513
Decernotinib
Decernotinib (USAN/INN)
Decernotinib (VX-509)
Decernotinib [USAN:INN]
Decernotinib(VX-509)
Decernotinib,VX-509
GTPL8309
KS-00001CYK
MZK2GP0RHK
SCHEMBL2630387
UNII-MZK2GP0RHK
VRT 831509
VRT-831509
VX 509
VX-509
VX-509 (Decernotinib)
VX509
Show/Hide
|
||||||||||||||||||
| Structure |
|
||||||||||||||||||
| Formula |
C18H19F3N6O
|
||||||||||||||||||
| Molecular Weight |
392.385
|
||||||||||||||||||
| Canonical SMILES |
CC[C@@](C)(Nc1ccnc(n1)-c1c[nH]c2ncccc12)C(=O)NCC(F)(F)F
Show/Hide
|
||||||||||||||||||
| InChI |
InChI=1S/C18H19F3N6O/c1-3-17(2,16(28)25-10-18(19,20)21)27-13-6-8-23-15(26-13)12-9-24-14-11(12)5-4-7-22-14/h4-9H,3,10H2,1-2H3,(H,22,24)(H,25,28)(H,23,26,27)/t17-/m1/s1
Show/Hide
|
||||||||||||||||||
| InChIKey |
ASUGUQWIHMTFJL-QGZVFWFLSA-N
|
||||||||||||||||||
| CAS |
944842-54-0
|
||||||||||||||||||
| Physicochemical Property |
"RO5" indicates the cutoff set by lipinski's rule of five: (1) Molecular weight less than 500 Dalton; (2) xlogp less than 5; (3) No more than 5 hbonddonor (Hydrogen Bond Donor Count); (4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count); (5) No more than 10 rotbonds (Rotatable Bond Count). Show/Hide
|
||||||||||||||||||
| Click to Show/Hide the External Link(s) of This Compound | |||||||||||||||||||
| PubChem ID | |||||||||||||||||||
| ChEMBL ID | |||||||||||||||||||
| DrugBank ID | |||||||||||||||||||
Clinical Information about the Compound